Niamh Coleman, MBBCH BAO PhD, is a fellow in the Department of Investigational Cancer Therapeutics (Phase I Program) Oncology at the University of Texas MD Anderson Cancer Center (MDACC). She undertook her medical oncology training in Ireland and completed Higher Specialist Training in Medical Oncology in Ireland in July 2017. Dr. Coleman pursued an extended period of clinical research, including a fellowship in phase I drug development and a translational PhD at the Royal Marsden Hospital and the Institute of Cancer Research, London, England.

Dr. Coleman has extensive experience in translational cancer research with a focus on resistance mechanisms and druggable kinases. Dr. Coleman’s main research interests have been focused on the clinical and translational development of novel inhibitors against receptor tyrosine kinases, such as MET and EGFR, and signaling pathways such as AKT/ PI3K/ MTOR. Dr. Coleman has expertise in the design, development and conduct of hypothesis-testing, biomarker-driven early phase clinical trials, well as the assessment of circulating tumour DNA (ctDNA) while on novel systemic therapies.